PATENT CLAIM ANALYSIS

Application Number: 16093990
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-05
Patent Classification: ["514", "232800"]

Abstract:
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonizes or partially agonizes) NLRP3 that are useful, e.g., for treating a condition, disease or disorder in which a decrease in NLRP3 activity (e.g., a condition, disease or disorder associated with repressed or impaired NLRP3 signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

Claim (Index 226):
The compound of  claim 216 , wherein R 1  is hydrogen.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 97.0
- Lexical Diversity: 2.01613
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15898258', '16094000', '15620396', '12813148', '13035640']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7826973383443521
- 35 USC 102 Novelty (BERT): 0.540390916449802
- Combined Prediction Score: 0.7584666961548971
- Mean Citation Score: 280.91243
- Max Citation Score: 390.9892
- Similarity Product: 228.947994823122

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test